Cefetamet

In response to the clinical diagnosis and treatment needs of common bacterial infections such as lower respiratory tract infections and urinary tract infections, cefetamet, a third-generation cephalosporin antibiotic, occupies an important clinical position due to its unique mechanism of action. It exerts a bactericidal effect by inhibiting the biosynthesis of bacterial cell walls, and has broad-spectrum antibacterial activity against both Gram-positive bacteria and Gram-negative bacteria. In particular, it is highly stable to β-lactamase, which can effectively reduce the risk of treatment failure for drug-resistant bacteria. Clinically, it is mainly used for the treatment of otitis media, sinusitis, pharyngitis, tonsillitis, acute bronchitis, acute exacerbation of chronic bronchitis, urinary tract infection, gonorrhea and other diseases caused by susceptible bacteria, and is applicable to infected adult and pediatric patients.

At present, the global market size of cefetamet exceeds 1.2 billion yuan. With the continuous release of demand for primary-level anti-infective diagnosis and treatment, the compound annual growth rate in the past three years has remained at around 4.7%. The domestic market has formed a competitive pattern dominated by generic drugs. More than 10 enterprises have obtained preparation approval documents. After the implementation of centralized procurement, the price has dropped by 68%, further promoting the clinical accessibility of the drug, and the substitution rate of generic drugs has exceeded 90%.

The original research enterprise of cefetamet is Roche, and the original research brand name is "Globocef". Its core compound patent expired in 2003, and all the preparation patents in major markets expired around 2008. The main dosage forms approved for the original research are cefetamet pivoxil dry suspension and tablets, with specifications including 90.65mg, 181.3mg and 362.6mg (calculated as cefetamet). Relevant dosage forms have been included in the FDA Reference Listed Drug Catalog, and China has also included them in the *Reference Listed Drug Catalog for Chemical Generic Drugs*. As of now, 12 domestic enterprises have obtained A status for their cefetamet API through CDE registration, and more than 30 other enterprises have obtained marketing approval for cefetamet pivoxil preparations. (Data as of October 2024, please refer to the official CDE website for the latest information)

CATO can provide a full set of cefetamet impurity reference standards. Most products are in regular stock. For stock orders, payment made before 16:00 can be shipped on the same day. All products meet the regulatory requirements of multiple regions such as Chinese Pharmacopoeia and FDA. The impurity structures are confirmed by complete spectra, which can meet the full-process R&D needs such as impurity research and consistency evaluation.